Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Director | May 04, 2022 | May 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2032-05-04 | Direct | 6,000 |
Reported balance
After 2022-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-04 · Grant · Acquired 6,000 · Balance 6,000 F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F2: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Rarick's board and committee services. |
Filing footnotes · ownership attribution and instrument terms
F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.
F2: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Rarick's board and committee services.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2022 Filed May 6, 2022 20:09 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001618835-22-000104 · wf-form4_165186773034453.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-05-04 F1 · derivative.exercise_price: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F1 · shares: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Rarick's board and committee services. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:14 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 5,000 | $1.20 | $5,990.00 |
DisclosureSEC source: 0001618835-21-000154 · wf-form4_162370163135768.xml · nonDerivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:15 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000111 · wf-form4_162093692202581.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Rarick's board and committee services. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:29 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 5,250 | $2.99 | $15,697.50 |
DisclosureSEC source: 0001618835-20-000204 · wf-form4_159251217994076.xml · nonDerivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:39 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000135 · wf-form4_158940237371677.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Rarick's board and committee services. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 01:22 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0001618835-20-000037 · wf-form4_158276652169035.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest on a monthly basis over 3 years upon completion of continuous service for the Issuer from the vesting commencement date of February 25, 2020. The option was awarded in connection with Dr. Rarick's appointment to the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.